PCI to continue as a high-level professional standard setting body
Chronicle Pharmabiz
|January 1, 2026
Following the landmark decision to retain the Pharmacy Council of India's (PCI) independent status under the Viksit Bharat Shiksha Adhishthan (VBSA) Bill, 2025, the legislation unveils a sophisticated new architecture for the profession.
This second phase of reform transitions the PCI from a traditional regulator into a high-level Professional Standard Setting Body (PSSB). This evolution ensures that while the Council moves away from direct administrative management of institutions, it gains unparalleled authority over the academic and clinical benchmarks of the discipline.
Diese Geschichte stammt aus der January 1, 2026-Ausgabe von Chronicle Pharmabiz.
Abonnieren Sie Magzter GOLD, um auf Tausende kuratierter Premium-Geschichten und über 9.000 Zeitschriften und Zeitungen zuzugreifen.
Sie sind bereits Abonnent? Anmelden
WEITERE GESCHICHTEN VON Chronicle Pharmabiz
Chronicle Pharmabiz
Telangana DCA busts unlicensed medical device unit in Sangareddy
IN a major enforcement action, the DCA of Telangana busted an unlicensed medical device manufacturing facility in Sangareddy District on December 23, 2025.
1 mins
January 1, 2026
Chronicle Pharmabiz
Motilal Oswal invests US$ 72 mn in Sensa Core
MOTILAL Oswal Alternates had Monde Oswal AlternatES made a significant minority investment of US$ 72 million in Sensa Core, an innovation-driven medical devices' company focused on advancing healthcare technology in India.
1 mins
January 1, 2026
Chronicle Pharmabiz
Odisha announces Pharma, Med Devices Policy 2025
MARKING a historic shift in the state's industrial landscape, chief minister Mohan Charan Majhi has officially unveiled the Odisha Pharmaceutical and Medical Devices Policy 2025 at the inaugural Odisha Pharma Summit in Bhubaneswar on December 16.
1 min
January 1, 2026
Chronicle Pharmabiz
Experts highlight policy intervention in pricing reforms
PRICING reforms must balance affordability with industry viability. Rational, transparent pricing models, volume-forprice contracts, and tiered pricing for non-essential therapies can sustain manufacturer participation going forward, highlights Dr Kunal Saxena, managing director, Rusan Pharma Ltd.
1 min
January 1, 2026
Chronicle Pharmabiz
Glenmark launches epinephrine in US market
GLENMARK PharmaceutiGcals Inc, USA (Glenmark) Glenannounced the launch of epinephrine injection USP, 30 mg/30 mL (1 mg/mL) multiple-dose vial.
1 min
January 1, 2026
Chronicle Pharmabiz
SSSIHMS, Siemens Healthineers ink research pact
SHRI Sathya Sai Institute of Higher Medical Sciences (SSSIHMS) and Siemens Healthineers have entered a strategic clinical research collaboration titled, 'Collaborative Clinical Research in Echocardiography.'
1 min
January 1, 2026
Chronicle Pharmabiz
PCI to continue as a high-level professional standard setting body
Following the landmark decision to retain the Pharmacy Council of India's (PCI) independent status under the Viksit Bharat Shiksha Adhishthan (VBSA) Bill, 2025, the legislation unveils a sophisticated new architecture for the profession.
1 mins
January 1, 2026
Chronicle Pharmabiz
Pondicherry refers multi-crore counterfeit medicine racket to CBI
As the Government of Pondicherry has officially handed over the massive counterfeit medicine scandal to the Central Bureau of Investigation (CBI) and the National Investigation Agency (NIA), the focus of the probe is shifting from the initial arrests to a series of alarming, unanswered questions.
1 mins
January 1, 2026
Chronicle Pharmabiz
AFDLHF announces boycott of MMGPA tender
THE All Food and Drug Licence Holders Foundation (AFDLHF) has announced a complete boycott of the Maharashtra Medical Goods Authority (MMGPA) tender process, citing serious concerns over the introduction of an unlawful and anti-competitive \"Bunch Bid\" clause impacting Pharma Micro, Small and Medium Enterprises (MSMEs).
1 mins
January 1, 2026
Chronicle Pharmabiz
Daiichi Sankyo & AstraZeneca's Enhertu approved in China
ENHERTU (trastuzumab deruxtecan) has been approved China for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 low (IHC 1+ or IHC 2+/ISH-) or HER2 ultralow (IHC 0 with membrane staining) breast cancer that has progressed on one or more endocrine therapies in the metastatic setting.
1 mins
January 1, 2026
Listen
Translate
Change font size

